Program
Ranibizumab
Also written as “ranibizumab”, “Ranibizumab 0.5 mg” and “rhuFab V2 (ranibizumab)”.
Its studies are mostly in Macular Degeneration · Macular Edema · Choroidal Neovascularization · Retinal Vein Occlusion · Vision Disorders, led by 16 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 560 open or running | phase 4since Jul 19, 2007 | Jan 11, 2006 | none ahead |
| Hoffmann-La Roche | 244 open or running | phase 4since Jan 13, 2011 | Mar 24, 2003 | Feb 4, 2027phase 3 · NCT04657289 |
| AbbVie | 31 open or running | phase 4since Aug 31, 2011 | Oct 16, 2008 | Jul 2031phase 2 · NCT05210803 |
| Samsung Bioepis | 20 open or running | phase 2since Dec 11, 2023 | Dec 11, 2023 | none ahead |
| Santen Pharmaceutical | 20 open or running | phase 2since Oct 1, 2008 | Oct 1, 2008 | none ahead |
| AO GENERIUM | 11 open or running | phase 3since Nov 30, 2020 | Nov 30, 2020 | none ahead |
| bioeq-gmbh | 10 open or running | phase 3since Nov 19, 2015 | Nov 19, 2015 | none ahead |
| Cynosure Lutronic | 10 open or running | phase 4since Nov 27, 2018 | Nov 27, 2018 | none ahead |
| Formycon | 10 open or running | phase 4since Nov 25, 2024 | Nov 25, 2024 | none ahead |
| Incepta Pharmaceuticals | 10 open or running | phase 3since Mar 5, 2024 | Mar 5, 2024 | none ahead |
| oraya-therapeutics-inc | 10 open or running | no phasesince Jan 24, 2012 | Jan 24, 2012 | none ahead |
| pfenex-inc | 10 open or running | phase 2since Apr 17, 2014 | Apr 17, 2014 | none ahead |
| Qilu Pharmaceutical | 10 open or running | phase 1since Oct 12, 2017 | Oct 12, 2017 | none ahead |
| qlt-inc | 10 open or running | phase 2since Jun 25, 2007 | Jun 25, 2007 | none ahead |
| shanghai-biomabs-pharmaceutical-co-ltd | 10 open or running | phase 1since May 6, 2021 | May 6, 2021 | none ahead |
| xbrane-biopharma-ab | 10 open or running | phase 3since Jan 8, 2019 | Jan 8, 2019 | none ahead |
Also a collaborator on its studies: regenxbio-inc, stada-arzneimittel-ag and macusight-inc.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 46 studies since Mar 11, 2011.
- Aug 5, 2020Phase 3 study in Diabetic RetinopathyHoffmann-La Roche · NCT04503551 · 174 enrolled · United States, Puerto Rico
- Sep 24, 2020Phase 2 study in Macular DegenerationHoffmann-La Roche · NCT04567303 · 177 enrolled · United States, Puerto Rico
- Nov 30, 2020AO GENERIUM's first study: phase 3 study in Macular DegenerationNew to AO GENERIUMAO GENERIUM · NCT04667039 · 408 planned · Russian Federation
- Dec 1, 2020Phase 3 study in Neovascular Age-related Macular Degeneration (nAMD)Hoffmann-La Roche · NCT04657289 · 451 enrolled · Argentina, Australia, Austria and more
- Apr 16, 2021Phase 4 study in Neovascular Age-related Macular DegenerationHoffmann-La Roche · NCT04853251 · 188 enrolled · United States
- May 6, 2021shanghai-biomabs-pharmaceutical-co-ltd's first study: phase 1 study in Wet Age-related Macular DegenerationNew to shanghai-biomabs-pharmaceutical-co-ltdshanghai-biomabs-pharmaceutical-co-ltd · NCT04884399 · 24 enrolled · China
- Oct 28, 2021Phase 3 study in Neovascular Age-Related Macular DegenerationHoffmann-La Roche · NCT05126966 · Argentina, Denmark, Greece and more
- Jan 14, 2022Phase 2 study in Neovascular Age-Related Macular Degeneration (nAMD)AbbVie · NCT05210803 · 116 planned · United States
- Sep 15, 2022Phase 3 study in Neovascular Age-related Macular DegenerationHoffmann-La Roche · NCT05562947 · 68 enrolled · China
- Dec 11, 2023Samsung Bioepis's first study: phase 2 study in Macular EdemaNew to Samsung BioepisSamsung Bioepis · NCT06176963 · 34 enrolled · Poland
- Mar 5, 2024Incepta Pharmaceuticals's first study: phase 3 study in Diabetic RetinopathyNew to Incepta PharmaceuticalsIncepta Pharmaceuticals · NCT06305416 · 70 enrolled · Bangladesh
- Nov 25, 2024Formycon's first study: phase 4 study in Macular DegenerationNew to FormyconFormycon · NCT06708624 · 31 enrolled · United States
- Feb 21, 2025Phase 3 study in Neovascular Age-related Macular DegenerationHoffmann-La Roche · NCT06847542 · 250 planned · Austria, Czechia, Denmark and more
- Apr 19, 2026Phase 2 study in Macular DegenerationSamsung Bioepis · NCT07550504 · 30 enrolled · Poland
Ahead
- Feb 4, 2027Primary completion: phase 3 study in Neovascular Age-related Macular Degeneration (nAMD)Hoffmann-La Roche · NCT04657289
- Jun 30, 2027Primary completion: phase 3 study in Neovascular Age-related Macular DegenerationHoffmann-La Roche · NCT05562947
- Jul 30, 2027Primary completion: phase 4 study in Neovascular Age-related Macular DegenerationHoffmann-La Roche · NCT04853251
- Nov 15, 2028Primary completion: phase 3 study in Neovascular Age-related Macular DegenerationHoffmann-La Roche · NCT06847542
TargetBeta
“A second-generation, recombinant humanized IgG1 kappa monoclonal antibody fragment directed against human vascular endothelial growth factor (VEGF) alpha”NCIt, by rule
“Vascular endothelial growth factor A inhibitor”ChEMBL 37, by rule
Other programs on VEGFA
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Bevacizumabrule | Hoffmann-La Roche | phase 4 | 250 |
| afliberceptrule | Regeneron Pharmaceuticals | phase 4 | 89 |
| faricimabrule | Hoffmann-La Roche | phase 4 | 17 |
| ivonescimabrule | Akeso | phase 3 | 48 |
| pumitamig | BioNTech | phase 3 | 34 |
| tivunatamig | Pfizer | phase 3 | 15 |
| suvemcitugrule | Simcere Pharmaceutical Group | phase 3 | 6 |
| Anti-PD-1/Anti-VEGF Bispecific Antibody SCTB14rule | Sinocelltech Group | phase 3 | 2 |
| surabgene lomparvovec | AbbVie | phase 3 | 2 |
| ABBV-1480 | RemeGen | phase 3 | 2 |
| HLX37 | Fosun Pharma | phase 3 | 2 |
| Anti-PD-1/Anti-VEGF-A Bispecific Antibody CR-001rule | Sichuan Kelun Pharmaceutical | phase 2 | 4 |
Studies
The newest 60 of 98 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07550504Macular Degeneration · Poland | 2 | Completed | Samsung Bioepis | Mar 31, 2026 | 30 |
| NCT06847542Neovascular Age-related Macular Degeneration · Austria, Czechia, Denmark and more | 3 | Recruiting | Hoffmann-La Roche | Nov 15, 2028 | 250 |
| NCT06708624Macular Degeneration · United States | 4 | Completed | Formycon | Aug 8, 2024 | 31 |
| NCT06305416Diabetic Retinopathy · Bangladesh | 3 | Completed | Incepta Pharmaceuticals | Mar 10, 2026 | 70 |
| NCT06176963Macular Edema · Poland | 2 | Completed | Samsung Bioepis | Nov 30, 2023 | 34 |
| NCT05562947Neovascular Age-related Macular Degeneration · China | 3 | Active, not recruiting | Hoffmann-La Roche | Jun 30, 2027 | 68 |
| NCT05210803Neovascular Age-Related Macular Degeneration (nAMD) · United States | 2 | By invitation | AbbVie | Jul 2031 | 116 |
| NCT05126966Neovascular Age-Related Macular Degeneration · Argentina, Denmark, Greece and more | 3 | Withdrawn | Hoffmann-La Roche | Jan 31, 2025 | 0 |
| NCT04884399Wet Age-related Macular Degeneration · China | 1 | Completed | shanghai-biomabs-pharmaceutical-co-ltd | Dec 22, 2022 | 24 |
| NCT04853251Neovascular Age-related Macular Degeneration · United States | 4 | Active, not recruiting | Hoffmann-La Roche | Jul 30, 2027 | 188 |
| NCT04657289Neovascular Age-related Macular Degeneration (nAMD) · Argentina, Australia, Austria and more | 3 | Active, not recruiting | Hoffmann-La Roche | Feb 4, 2027 | 451 |
| NCT04667039Macular Degeneration · Russian Federation | 3 | Recruiting | AO GENERIUM | Aug 15, 2024 | 408 |
| NCT04567303Macular Degeneration · United States, Puerto Rico | 2 | Completed | Hoffmann-La Roche | Aug 25, 2026 | 177 |
| NCT04503551Diabetic Retinopathy · United States, Puerto Rico | 3 | Completed | Hoffmann-La Roche | Oct 3, 2022 | 174 |
| NCT03927690Macular Degeneration · United States, Germany, Puerto Rico and more | 2 | Completed | Novartis | Jun 17, 2022 | 91 |
| NCT03805100Macular Degeneration · United States, Bulgaria, Czechia and more | 3 | Completed | xbrane-biopharma-ab | May 11, 2021 | 582 |
| NCT03759860Diabetic Macular Edema · Korea, Republic of | 4 | UNKNOWN | Cynosure Lutronic | Jul 30, 2019 | 12 |
| NCT03312283Wet Age-related Macular Degeneration · China | 1 | Completed | Qilu Pharmaceutical | Apr 2, 2019 | 48 |
| NCT03211234Macular Degeneration · United States, Philippines | 2 | Completed | Santen Pharmaceutical | Dec 31, 2019 | 76 |
| NCT02878681Visual Impairment Due to Diabetic Macular Edema | 4 | Withdrawn | Novartis | Sep 2017 | 0 |
| NCT02698566Macular Edema · United States | 3 | Completed | Hoffmann-La Roche | Apr 5, 2016 | 35 |
| NCT02634970Neovascularization, Pathologic | 4 | Withdrawn | Novartis | Dec 2017 | 0 |
| NCT02640664Retinopathy of Prematurity · United States, Austria, Belgium and more | 3 | Completed | Novartis | Apr 21, 2022 | 180 |
| NCT02611778Macular Degeneration · Austria, Czechia, France and more | 3 | Completed | bioeq-gmbh | Dec 2017 | 712 |
| NCT02577107Macular Degeneration · China | 4 | Completed | Novartis | Jul 9, 2016 | 12 |
| NCT02510794Macular Degeneration · United States | 2 | Completed | Hoffmann-La Roche | Apr 10, 2018 | 225 |
| NCT02484690Choroidal Neovascularization · United States | 2 | Completed | Hoffmann-La Roche | Sep 26, 2017 | 273 |
| NCT02375971Retinopathy of Prematurity · United States, Austria, Belgium and more | 3 | Completed | Novartis | Dec 14, 2017 | 224 |
| NCT02366468Diabetic Retinopathy · Germany | 4 | Completed | Novartis | Jun 8, 2017 | 135 |
| NCT02259088Vision Disorders · China | 3 | Completed | Novartis | Jan 17, 2017 | 384 |
| NCT02258009Visual Impairment Due to Diabetic Macular Edema · Germany | 4 | Withdrawn | Novartis | Oct 2016 | 0 |
| NCT02257632Wet Age-Related Macular Degeneration · Germany | 4 | Completed | Novartis | Mar 20, 2017 | 41 |
| NCT02161575Macular Degeneration · Germany, United Kingdom | 4 | Completed | Novartis | Sep 14, 2017 | 103 |
| NCT02121353Macular Degeneration · New Zealand | 2 | Completed | pfenex-inc | Jan 2016 | 25 |
| NCT02130024Macular Degeneration · Australia | 4 | Completed | Novartis | Nov 15, 2017 | 281 |
| NCT02034006Myopia, Degenerative · Italy | 3 | Completed | Novartis | Jul 15, 2016 | 200 |
| NCT02032173Macular Edema · France | 3 | Terminated | Novartis | Apr 29, 2015 | 31 |
| NCT01986907Macular Degeneration · Italy | 4 | Completed | Novartis | Jun 15, 2016 | 1,049 |
| NCT01972789Subfoveal Choroidal Neovascularization CNV Secondary to Wet Age-related Macular Degeneration AMD · Australia | 4 | Completed | Novartis | Feb 28, 2017 | 349 |
| NCT01976338Macular Edema · China, Hong Kong, Indonesia and more | 3 | Completed | Novartis | Mar 28, 2016 | 283 |
| NCT01976312Retinal Vein Occlusion · China, Hong Kong, India and more | 3 | Completed | Novartis | Mar 14, 2016 | 252 |
| NCT01958918Neovascular Age-related Macular Degeneration · Austria, Belgium, Denmark and more | 4 | Completed | Novartis | Nov 22, 2016 | 712 |
| NCT01948830Macular Degeneration · Belgium, Chile, Croatia and more | 3 | Completed | Novartis | Nov 19, 2015 | 650 |
| NCT01922102Choroidal Neovascularization · China, Hong Kong, India and more | 3 | Completed | Novartis | Sep 14, 2016 | 457 |
| NCT01908816Choroidal Neovascularization · France | 3 | Completed | Novartis | Jan 8, 2016 | 270 |
| NCT01846299Macular Edema · Australia, Belgium, Canada and more | 3 | Completed | Novartis | Sep 2015 | 181 |
| NCT01840410Choroidal Neovascularization · Australia, Canada, Czech Republic and more | 3 | Completed | Novartis | Nov 2015 | 183 |
| NCT01780935Neovascular Age-related Macular Degeneration · Argentina, Austria, Canada and more | 3 | Completed | Novartis | Jul 9, 2015 | 671 |
| NCT01775124Macular Degeneration · China | 4 | Completed | Novartis | Nov 23, 2015 | 332 |
| NCT01594281Proliferative Diabetic Retinopathy (PDR) · Germany | 2 | Completed | Novartis | Nov 30, 2016 | 107 |
| NCT01599650Retinal Vein Occlusion · Australia, Canada, Czech Republic and more | 3 | Completed | Novartis | May 2015 | 455 |
| NCT01580020Retinal Vein Occlusion · Germany | 4 | Completed | Novartis | Oct 2014 | 175 |
| NCT01535261Macular Edema · Australia, Austria, Canada and more | 3 | Completed | Novartis | Mar 2015 | 357 |
| NCT01521819Macular Degeneration · Italy | – | UNKNOWN | oraya-therapeutics-inc | Aug 2013 | 12 |
| NCT01442064Macular Edema | – | Completed | Hoffmann-La Roche | Jul 2010 | 608 |
| NCT01427751Retinal Vein Occlusion · France, Germany, Israel and more | 4 | Completed | AbbVie | Nov 4, 2014 | 307 |
| NCT01396083Vision Disorders · Germany, Hungary, Poland and more | 3 | Completed | Novartis | Jan 2014 | 243 |
| NCT01396057Vision Disorders · Czech Republic, Germany, Hungary and more | 3 | Completed | Novartis | Jun 2013 | 244 |
| NCT01377597Retinal Vein Occlusion · Japan | 3 | Completed | Novartis | Apr 2012 | 47 |
| NCT01315275Vision Disorders · France | 4 | Completed | Novartis | Aug 2012 | 394 |
How it is read
Names in the registry
- “Ranibizumab”, 40 entries
- “ranibizumab”, 18 entries
- “Ranibizumab 0.5 mg”, 11 entries
- “rhuFab V2 (ranibizumab)”, 6 entries
- “Ranibizumab 0.5mg”, 4 entries
Conditions, from the studies’ own filings
- Macular Degeneration, 41 studies
- Macular Edema, 22 studies
- Choroidal Neovascularization, 15 studies
- Retinal Vein Occlusion, 7 studies
- Vision Disorders, 6 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.